31088-06-9

Basic information

• Product Name: 5'-palmitoyl cytarabine
• Synonyms: 5'-palmitoyl cytarabine;((2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl palmitate
• CAS NO: 31088-06-9
• Molecular Formula: C25H43N3O6
• Molecular Weight: 481.62542
• Mol File: 31088-06-9.mol

Chemical Properties

• Boiling Point: 579.27°C (rough estimate)
• Flash Point: 337.3°C
• Appearance: /
• Density: 1.1644 (rough estimate)
• Vapor Pressure: 9.53E-19mmHg at 25°C
• Refractive Index: 1.7120 (estimate)
• CAS DataBase Reference: 5'-palmitoyl cytarabine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-palmitoyl cytarabine(31088-06-9)
• EPA Substance Registry System: 5'-palmitoyl cytarabine(31088-06-9)

Safety Data

• Hazardous Substances Data: 31088-06-9(Hazardous Substances Data)

Usage

Safety Profile

A poison by intraperitoneal route. When heated to decomposition it emits toxic vapors of NOx.

InChI:InChI=1/C25H43N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-21(29)33-18-19-22(30)23(31)24(34-19)28-17-16-20(26)27-25(28)32/h16-17,19,22-24,30-31H,2-15,18H2,1H3,(H2,26,27,32)

Relevant articles and documents

Organic compounds and compositions of ara-cytidine

5'-Esters of ara-cytidine (1-β-D-arabinofuranosylcytosine) are prepared by reacting ara-cytidine with β,β,β-trihaloethoxycarbonyl halide or other protective agency to form a protective amido group on the primary amino nitrogen of ara-cytidine and then reacting the thus-protected compound with a reagent reactive with the 5'-O-hydroxyl group, e.g., an acylating agent, to form the 5'-O-derivative. The β,β,β-trihaloethoxycarbonyl or other protective group is then removed. Alternately, the primary amino group of ara-cytidine can be protected from acylation by protonation. The 5'-O-derivatives in their free base or salt form are characterized in that they display the property of sustained release of the compound, ara-cytidine, when administered intramuscularly or subcutaneously. Ara-cytidine is known for its anti-viral action and for its usefulness as an agent for controlling leukemias, including acute leukemia, and the sustained release property extends the usefulness of ara-cytidine for these purposes and as an immunosuppressive agent. The 5'-O-derivatives of this invention can also be administered orally.

Cytidine nucleoside compound

5'-Esters of ara-cytidine (1-β-D-arabinofuranosylcytosine) are prepared by reacting ara-cytidine with β,β,β-trihaloethoxycarbonyl halide or other protective agency to form a protective amido group on the primary amino nitrogen of ara-cytidine and then reacting the thus-protected compound with a reagent reactive with the 5'-O-hydroxyl group, e.g., an acylating agent, to form the 5'-O-derivative. The β,β,β-trihaloethoxycarbonyl or other protective group is then removed. Alternately, the primary amino group of ara-cytidine can be protected from acylation by protonation. The 5'-O-derivatives in their free base of salt form are characterized in that they display the property of sustained release of the compound, ara-cytidine, when administered intramuscularly or subcutaneously. Ara-cytidine is known for its anti-viral action and for its usefulness as an agent for controlling leukemias, including acute leukemia, and the sustained release property extends the usefulness of ara-cytidine for these purposes and as an inmunosuppressive agent. The 5'-O-derivartives of this invention can also be administered orally.